Kangmei Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Kangmei Pharmaceutical has a total shareholder equity of CN¥7.1B and total debt of CN¥12.2M, which brings its debt-to-equity ratio to 0.2%. Its total assets and total liabilities are CN¥14.2B and CN¥7.1B respectively. Kangmei Pharmaceutical's EBIT is CN¥277.6M making its interest coverage ratio -7.3. It has cash and short-term investments of CN¥773.6M.
Key information
0.2%
Debt to equity ratio
CN¥12.20m
Debt
| Interest coverage ratio | -7.3x |
| Cash | CN¥773.59m |
| Equity | CN¥7.08b |
| Total liabilities | CN¥7.12b |
| Total assets | CN¥14.19b |
Recent financial health updates
Is Kangmei Pharmaceutical (SHSE:600518) A Risky Investment?
Oct 28
We Think Kangmei Pharmaceutical (SHSE:600518) Can Stay On Top Of Its Debt
Jun 17Recent updates
Subdued Growth No Barrier To Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) With Shares Advancing 35%
Nov 08We Think Kangmei Pharmaceutical's (SHSE:600518) Robust Earnings Are Conservative
Nov 06Is Kangmei Pharmaceutical (SHSE:600518) A Risky Investment?
Oct 28What Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) P/S Is Not Telling You
Aug 03We Think Kangmei Pharmaceutical (SHSE:600518) Can Stay On Top Of Its Debt
Jun 17Kangmei Pharmaceutical's (SHSE:600518) Performance Is Even Better Than Its Earnings Suggest
May 06Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Price Is Out Of Tune With Revenues
Apr 10Financial Position Analysis
Short Term Liabilities: 600518's short term assets (CN¥7.0B) exceed its short term liabilities (CN¥4.9B).
Long Term Liabilities: 600518's short term assets (CN¥7.0B) exceed its long term liabilities (CN¥2.2B).
Debt to Equity History and Analysis
Debt Level: 600518 has more cash than its total debt.
Reducing Debt: 600518's debt to equity ratio has reduced from 119% to 0.2% over the past 5 years.
Debt Coverage: 600518's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 600518 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 01:10 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kangmei Pharmaceutical Co., Ltd. is covered by 17 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Pei Hui Tang | Chasing Securities |
| Peng Zou | China International Capital Corporation Limited |